Chronic Conditions Month 2024
Renal
- Friday 10 May 2024
- 13.00–15.00
The agenda
13.00–13:45
Improving the care of people with chronic kidney disease (CKD)
- Treatment approaches to prevent or delay progression of CKD and the role of Primary Care
- Developing an integrated approach to the management of people with CKD (e.g. new models of care, optimising patient education, addressing multiple long-term conditions and healthcare inequalities
- Andrew Frankel, Chair: Peter Bagshaw
13:45-14:20
Protecting cardiorenal function in patients with T2D: understanding the practicalities of treatment
This is a promotional symposium sponsored and organised by AstraZeneca, intended for GB HCPs only.
- Beverley Bostock, Advanced Nurse Practitioner, Gloucestershire
14:20 - 15:00
Removing barriers to the care of people with CKD
- Removing the barrier of hyperkalaemia to optimisation of CKD
- Andrew Frankel, Chair: Peter Bagshaw
The speakers
Andrew Frankel
Consultant Renal Physician
Andrew has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995. He has extensive experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease. Andrew has Maintained a significant research interest in relation to diabetes and kidney, both in terms of how diabetes affects the kidneys leading to deterioration in kidney function, but also in relation to how the presence of kidney disease influences the management of diabetes.
He is published in relation to assessment of renal complications in people with diabetes and obesity. He has also played a significant role in the development of UK national guidelines on the management of diabetes in the context of kidney disease.
Andrew is joint editor of the UK Kidney Association guidelines on the use of SGLT2I in adults with chronic kidney disease. He is also an educational leader supporting the next generation of doctors, having been the director Imperial’s Foundation School from its inception to 2010, London lead for Foundation Training 2010 to 2013 and Postgraduate Dean for South London from 2013 and 2018.
Peter Bagshaw
Clinical Lead in Dementia and Mental Health, South Glos CCG, and Director of the South West Clinical Network for Dementia
Peter Bagshaw has been a GP in for over 30 years, and is currently a partner at Minehead Medical Centre.
He is currently the Mental Health and Dementia Clinical Lead for Somerset CCG, Director of the South West Dementia Clinical Network for Dementia, and Improving Access to Psychological Therapies (IAPT) Clinical Network Lead. He is a member of the National Improvement and Assessment Framework board, Chair of the South West IAPT Expert Reference Group, and Editor for the Dementia and Mental Health section of the online magazine Chronic Conditions.
His outside interests include painting, quantum mechanics and karate. He has written a book on the nature of reality, and is co-author of the recently published Older People’s Mental Health Primer.
Beverley Bostock
RGN, PgDip (Diabetes) MSc (Respiratory Care), MA (Medical Ethics and Law)
Bev is an Advanced Nurse Practitioner working in general practice in Gloucestershire. She has a special interest in long-term conditions, specifically diabetes, chronic kidney disease, cardiovascular disease, heart failure and the management of comorbidities including asthma and COPD. She is Editor in Chief of Practice Nurse Journal and is a Council Member for the Primary Care Cardiovascular Society. She has taken part in various national BP and lipids optimisation groups and has published a range of articles in different journals on the management of long-term conditions. Bev has developed and delivered accredited modules in cardiorenal metabolic disease and is a PhD researcher with Edinburgh Napier University.
Therapy webcast sponsor
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide.
With a proud 100-year heritage in advancing UK science, today AstraZeneca is the UK’s leading biopharmaceutical company. AstraZeneca is based in six different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,600 employees work in research and development, manufacturing, supply, sales and marketing. We supply around 35 different medicines to the NHS.
